Dermapharm Holding SE
0
0
0%

Financials

Income statement

Fiscal date 2024 2023 2022 2021
Total reported revenue 1.2B 1.1B 1.0B 942.9M
Cost of revenue 413.7M 416.2M 363.9M 322.2M
Gross profit 767.1M 719.2M 660.8M 620.7M
Operating expense
Research & development 11.5M 10.6M 13.2M 14.2M
Selling general and admin 88.4M 95.3M 66.7M 65.9M
Other operating expenses 79.3M 65.1M 52.3M 32.5M
Operating income 214.7M 180.1M 242.0M 287.0M
Non operating interest income
Income 14.0M 2.5M 325K 4.0M
Expense 58.4M 55.0M 12.3M 8.8M
Other income expense
Pretax income 172.0M 106.0M 216.3M 293.0M
Tax provision 60.3M 45.5M 83.7M 84.1M
Net income 111.7M 60.5M 132.6M 208.9M
Basic EPS 2.1 1.2 2.5 3.9
Diluted EPS 2.1 1.2 2.5 3.9
Basic average shares 53.8M 53.8M 53.8M 53.8M
Diluted average shares 53.8M 53.8M 53.8M 53.8M
EBITDA 320.1M 260.8M 328.5M 348.3M
Net income from continuing op. 172.0M 106.0M 216.3M 293.0M
Minority interests 2.1M 1.8M 1.6M 679K
Preferred stock dividends 0 0 0 0
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Market closed

Exchange is currently closed
Pre-market opens in 8 hours 14 minutes

23:45
00:00
08:55
17:35
23:59

Trading Hours (Monday - Friday):

Pre-market
08:00 - 08:55
Main market
08:55 - 17:35
Post-market
17:35 - 17:50
All times are displayed in the Europe/Vienna timezone (CET, UTC+01:00).